News
Herceptin now approved in the EU for patients with HER2-positive advanced stomach cancer
More Information
Early Breast Cancer
Herceptin delivers high cure rates for women with HER2-positive early breast cancer
Metastatic Breast Cancer
Herceptin extends the lives of women with
HER2-positive metastatic disease
More
Targeting HER2
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer has a poor prognosis, with a high rate of recurrence and short disease-free intervals.
HER2 testing
Accurate HER2 testing is essential to correctly identify patients who may benefit from Herceptin.
- Disclaimer: Herceptin.net is a comprehensive resource for healthcare professionals outside the US. If you are a US resident please visit www.herceptin.com. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
- © 2010 F. Hoffmann-La Roche Ltd.